How does ivabradine compare to other pharmacological agents used in heart failure management?

Article Ivabradine Therapy in Heart Failure Management: Optimizing O...

Ivabradine offers a unique mechanism of action compared to other pharmacological agents used in heart failure management. Here's how ivabradine compares to some commonly used medications:

Beta-Blockers: Both ivabradine and beta-blockers reduce heart rate, but they do so through different mechanisms. Beta-blockers exert their effects by blocking beta-adrenergic receptors, leading to decreased sympathetic activity and inhibition of the effects of catecholamines like adrenaline and noradrenaline. In contrast, ivabradine selectively inhibits the If current in the sinoatrial node, resulting in a reduction in heart rate without affecting myocardial contractility. While beta-blockers remain a cornerstone of heart failure therapy, ivabradine may be considered as an adjunctive treatment in patients with symptomatic heart failure who remain tachycardic despite optimal beta-blocker therapy or have contraindications to beta-blocker use.

ACE Inhibitors/ARBs: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are used to inhibit the renin-angiotensin-aldosterone system (RAAS), leading to vasodilation, reduced sodium and water retention, and improved cardiac remodeling in heart failure. These medications have demonstrated efficacy in reducing mortality and hospitalizations in heart failure patients with reduced ejection fraction. Ivabradine, on the other hand, primarily targets heart rate reduction and does not directly affect neurohormonal pathways like the RAAS.

Aldosterone Antagonists: Aldosterone antagonists, such as spironolactone and eplerenone, block the effects of aldosterone, a hormone that promotes sodium and water retention and myocardial fibrosis. These medications are used in heart failure patients with reduced ejection fraction to reduce morbidity and mortality. Ivabradine's mechanism of action is distinct from aldosterone antagonists and primarily focuses on heart rate reduction rather than neurohormonal blockade.

Diuretics: Diuretics, such as furosemide and bumetanide, are used to relieve symptoms of fluid overload in heart failure patients by promoting diuresis and reducing fluid retention. While diuretics address volume overload, they do not directly target underlying neurohormonal activation or heart rate control like ivabradine does.

SGLT2 Inhibitors: Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, have emerged as a novel class of medications with proven benefits in heart failure management. These agents reduce heart failure hospitalizations and cardiovascular mortality by promoting diuresis, reducing blood pressure, and improving cardiac function. SGLT2 inhibitors target glucose and sodium reabsorption in the kidney, whereas ivabradine focuses on heart rate reduction.

Overall, ivabradine offers a unique therapeutic approach in heart failure management by selectively reducing heart rate without affecting myocardial contractility. While it is not a substitute for other evidence-based medications, it may complement standard therapy in select patients to optimize symptom control and improve outcomes. The choice of pharmacological agents in heart failure management should be individualized based on patient characteristics, comorbidities, and treatment goals, with consideration of the existing evidence and guidelines.

Ahmad KAMAL Ariffin

Ivabradine is good esp in acute HF...it doesnt really reduce CO , knowing acute HF involves reduction of CO in which SBP can be low/hypotension.

Indications include HR > 70 bpm even after optimal use of beta blocker, if not mistaken LVEF < 35% and patient must have NSR@normal sinus rhythm

Alok Kumar Bharti

FDA approved the role of Ivabradine Iin symptomatic HF. Uniqueness of this drug is that it selectively inhibit Funnny Na channel in SA node , thus decreasing HR without affecting contractility of heart . Although Increase in HR is a compensatory mechanism in HF patients but Decrease in HR in such a way that doesn’t comprise CO

P.s. Banerjee

Ivabradine,used as an adjuvant therapy in HefRef with or without Beta1 selective blocker,but it's not considered a major drug in HeFref.

Detection and Identification of Amanitins in the Wood-Rotting Fungi Galerina fasciculata andGalerina helvoliceps

Edible mushrooms and their cultivation

Does anyone know an alternative product for cardiac Troponin T antibody for Immunofluorescence (Thermo # MA512960)?

For modelling epoxy-based matrices (in composites), which model in ABAQUS is the most suitable, Concrete damaged plasticity or Drucker-Prager model?

How can misfit between business requirents and ERP system business process be reduced?

How to perform Kaplan-meier survival analysis in SPSS?

Hello .Ineed a researchs about systolic heart failure any one can help me ?

Does euthanasia by CO2 inhalation cause NF-kB activation in mouse heart or body in general?

Discrete solution , process hf3d error: Failure in solving matrix - how to solve this error in hfss?

Is there any method I can use to isolate single cells (i.e cardiomyocytes and non-cardiomyocytes) from snap from rat heart tissue?

Continuum Damage in ANSYS Workbench?

How to solve "Insufficient data specified to develop the failure surface for material 1" in ANSYS APDL?